Cited by 115Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma

Calles, Antonio, Sholl, Lynette M., Rodig, Scott J., Pelton, Ashley K., Hornick, Jason L., Butaney, Mohit, Lydon, Christine, Dahlberg, Suzanne E., Oxnard, Geoffrey R., Jackman, David M., Jänne, Pasi A.·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-3112

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: LKB1 loss is common in lung cancer, but no assay exists to efficiently evaluate the presence or absence of LKB1. We validated an IHC assay for LKB1 loss and determined the impact of LKB1 loss in KRAS-mutant non–small cell lung cancer (NSCLC). Experimental Design: We optimized and validated an IHC assay for LKB1 (clone Ley37D/G6) using a panel of lung cancer cell lines and tumors with known LKB1 mutations, including 2 patients with Peutz–Jeghers syndrome (PJS) who developed lung adenocarcinoma. We retrospectively analyzed tumors for LKB1 using IHC from 154 KRAS-mutant NSCLC patients, including 123 smokers and 31 never-smokers, and correlated the findings with patient and tumor characteristics and clinical outcome. Results: LKB1 expression was lost by IHC in 30% of KRAS-mutant NSCLC (smokers 35% vs. never-smokers 13%, P = 0.017). LKB1 loss did not correlate with a specific KRAS mutation but was more frequent in tumors with KRAS transversion mutations (P = 0.029). KRAS-mutant NSCLC patients with concurrent LKB1 loss had a higher number of metastatic sites at the time of diagnosis (median 2.5 vs. 2, P = 0.01), higher incidence of extrathoracic metastases (P = 0.01), and developed brain metastasis more frequently (48% vs. 25%, P = 0.02). There was a nonsignificant trend to worse survival in stage IV KRAS-mutant NSCLC patients with LKB1 loss. Conclusions: LKB1 IHC is a reliable and efficient assay to evaluate for loss of LKB1 in clinical samples of NSCLC. LKB1 loss is more common in smokers, and is associated with a more aggressive clinical phenotype in KRAS-mutant NSCLC patients, accordingly to preclinical models. Clin Cancer Res; 21(12); 2851–60. ©2015 AACR.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-3112

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I. P. M., Avizienyte, E., Roth, S., Loukola, A., Bignell, G. R., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,680
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1
Lizcano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudeau, J., Hawley, S. A., Udd, L., Mäkelä, T. P., Hardie, D. G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600110 · Cited by 1,381
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase
Jenne, D. E., Reomann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Müller, O., Back, W. E., & Zimmer, M. (1998) · Nature Genetics · doi:10.1038/ng0198-38 · Cited by 1,201
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
AMPK is a direct adenylate charge-regulated protein kinase
Oakhill, J. S., Steel, R., Chen, Z.-P., Scott, J. W., Ling, N., Tam, S., & Kemp, B. E. (2011) · Science · doi:10.1126/science.1200094 · Cited by 612
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Adjei, A. A., Cohen, R. B., Franklin, W. A., Morris, C. D., Wilson, D. M., Molina, J. R., Hanson, L. J., Gore, L., Chow, L. Q. M., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 568
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 6×
“However, in Kras G12D/Lkb1 / GEMMS, selumetinib/docetaxel was significantly less effective (19).”
BackgroundResultInfluentialSelf-citation
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 436
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
Cardarella, S., Ogino, A., Nishino, M., Butaney, M., Shen, J., Lydon, C., Yeap, B. Y., Sholl, L. M., Johnson, B. E., & Janne, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0657 · Cited by 382
Self-citation
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Prevalence and specificity of LKB1 genetic alterations in lung cancers
Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., Nakamoto, M., Shimizu, E., Minna, J. D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210418 · Cited by 284
A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndrome
Sánchez‐Céspedes, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210594 · Cited by 233
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
Relationship Between K-ras Oncogene Activation and Smoking in Adenocarcinoma of the Human Lung
Slebos, R. J. C., Hruban, R. H., Dalesio, O., Mooi, W. J., Offerhaus, G. J. A., & Rodenhuis, S. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.14.1024 · Cited by 202
Growth arrest by the LKB1 tumor suppressor: induction of p21WAF1/CIP1
Tiainen, M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.13.1497 · Cited by 200
LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling
Gao, Y., Xiao, Q., Ma, H.-M., Li, L., Liu, J., Feng, Y., Fang, Z., Wu, J., Han, X., Zhang, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004952107 · Cited by 190
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung
Slebos, R. J. C. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90232-9 · Cited by 188
Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Ji, H., Wang, Z., Perera, S. A., Li, D., Liang, M., Zaghlul, S., McNamara, K. L., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 176
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
Steckel, M., Molina‐Arcas, M., Weigelt, B., Marani, M., Warne, P. H., Kuznetsov, H. S., Kelly, G. P., Saunders, B., Howell, M. T., Downward, J., et al. (2012) · Cell Research · doi:10.1038/cr.2012.82 · Cited by 174
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
Koivunen, J. P., Kim, J., Lee, J., Rogers, A. M., Park, J. O., Zhao, X., Naoki, K., Okamoto, I., Nakagawa, K., Yeap, B. Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604469 · Cited by 168
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 159
Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
Kim, H. R., Shim, H. S., Chung, J.-H., Lee, Y. J., Hong, Y. K., Rha, S. Y., Kim, S. H., Ha, S., Kim, S. K., Chung, K. S., et al. (2011) · Cancer · doi:10.1002/cncr.26311 · Cited by 149
Guanosine triphosphatase stimulation of oncogenic Ras mutants
Ahmadian, M. R., Zor, T., Vogt, D., Kabsch, W., Selinger, Z., Wittinghofer, A., & Scheffzek, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7065 · Cited by 144
Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer
Carretero, J., Medina, P. P., Blanco, R., Smit, L., Tang, M., Roncador, G., Maestre, L., Conde, E., López‐Ríos, F., Clevers, H. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209951 · Cited by 143
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
Yu, H. A., Sima, C. S., Shen, R., Kass, S. L., Gainor, J. F., Shaw, A. T., Hames, M. L., Iams, W. T., Aston, J. L., Lovly, C. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000432 · Cited by 137
Self-citation
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer
Chaux, A., Peskoe, S. B., González-Roibón, N., Schultz, L., Albadine, R., Hicks, J. L., Marzo, A. M. D., Platz, E. A., & Netto, G. J. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.104 · Cited by 135
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Mahoney, C., Choudhury, B., Davies, H. R., Edkins, S., Greenman, C., van Haaften, G. W., Mironenko, T., Santarius, T., Stevens, C., Stratton, M. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604886 · Cited by 128
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
Gill, R. K., Yang, S.-H., Meerzaman, D. M., Mechanic, L. E., Bowman, E. D., Jeon, H.-S., Roy‐Chowdhuri, S., Shakoori, A., Dracheva, T., Hong, K.-M., et al. (2011) · Oncogene · doi:10.1038/onc.2011.98 · Cited by 125
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene
Carretero, J., Medina, P. P., Pı́o, R., Montuenga, L. M., & Sánchez‐Céspedes, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207502 · Cited by 114
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
Self-citation
LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis
Marcus, A. I., & Zhou, W. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fbc28a · Cited by 76
Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
Meador, C. B., Micheel, C., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1591 · Cited by 68
The role of LKB1 in lung cancer
Sánchez‐Céspedes, M. (2011) · Familial Cancer · doi:10.1007/s10689-011-9443-0 · Cited by 66
Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas
Conde, E., Suárez‐Gauthier, A., García-García, E., López‐Ríos, F., Encuentra, Á. L., García‐Luján, R., Morente, M. M., Sánchez-Verde, L., & Sánchez‐Céspedes, M. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.01.022 · Cited by 59
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice
Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Boucher, D. H., Canepa, H. M., Kent, M. S., Gangadharan, S. P., Majid, A., Kocher, O. N., Goldstein, M. A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.013 · Cited by 56
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
Kelly, K. L., Mazières, J., Leighl, N. B., Barlési, F., Zalcman, G., Gordon, M. S., Reckamp, K. L., Gandara, D. R., Gomez‐Roca, C., Bennouna, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8027 · Cited by 42
Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
Takamochi, K., Oh, S., & Suzuki, K. (2013) · Oncology Letters · doi:10.3892/ol.2013.1551 · Cited by 36
Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers
Varghese, A. M., Sima, C. S., Chaft, J. E., Johnson, M. L., Riely, G. J., Ladanyi, M., & Kris, M. G. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827914ea · Cited by 33
Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas
Fang, R., Zheng, C., Sun, Y., Han, X., Gao, B., Li, C., Liu, H., Wong, K., Liu, X., Chen, H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000056 · Cited by 27
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
Gandara, D. R., Hiret, S., Blumenschein, G. R., Barlési, F., Delord, J., Madelaine, J., Infante, J. R., Reckamp, K. L., Lara, P. N., Audebert, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8028 · Cited by 27

Sorted by citations

Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Rekhtman, N., Pietanza, M. C., Hellmann, M. D., Naidoo, J., Arora, A., Won, H. H., Halpenny, D. F., Wang, H., Tian, S. K., Litvak, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2946 · Cited by 488
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Lou, Y., Diao, L., Parra, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 452

See all 115

Authors: Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., & Jänne, P. A.
Affiliations: Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
1Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
ORCID: Calles, Antonio
Sholl, Lynette M.
Rodig, Scott J.
Hornick, Jason L.
Butaney, Mohit
Dahlberg, Suzanne E.
Oxnard, Geoffrey R.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-06-14
Volume: 21
Issue: 12
Pages: 2851-2860
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-3112
OpenAlex: W2129277646
Cited by: 115
References: 50
Citations by year: 2026: 2 · 2025: 12 · 2024: 7 · 2023: 9 · 2022: 14 · 2021: 16 · 2020: 12 · 2019: 11 · 2018: 10 · 2017: 6 · 2016: 13 · 2015: 3
FWCI: 8.45
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: LKB1 loss, KRAS-mutant non-small cell lung cancer, lung adenocarcinoma, Peutz-Jeghers syndrome, smoking, metastasis, brain metastases, prognostic factors, tumor aggressiveness
MeSH terms: Adenocarcinoma of Lung, AMP-Activated Protein Kinase Kinases, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Genotype, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Risk Factors, Biomarkers, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Disease Progression, Cell Line, Tumor, Kaplan-Meier Estimate, Young Adult, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks